GlassScriptPhysician profile
Aziz Kamali
NPI 1306923883
$22,154.82
in general payments reported to CMS, 2019-2025
61 companies · $4,031 in 2025
The $4,031 reported for 2025 was more than what 97% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,208 · 2020: $3,393 · 2021: $3,048 · 2022: $3,192 · 2023: $2,922 · 2024: $3,361 · 2025: $4,031.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $10K · Education: $17.44.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $10,295.61 |
| Education | $17.44 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $2,194.97 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Boehringer Ingelheim Pharmaceuticals, INC. | $1,854.22 | 2019-2025 | Jardiance, Ofev |
| Astrazeneca Pharmaceuticals LP | $1,493.31 | 2019-2025 | Airsupra, Breztri, Farxiga |
| Ucb, INC. | $1,139.05 | 2020-2025 | Fintepla, Briviact, Bimzelx |
| Abbvie INC. | $1,084.05 | 2020-2025 | |
| Corcept Therapeutics | $972.95 | 2024-2025 | Korlym |
| Pfizer INC. | $956.39 | 2019-2025 | |
| Sumitomo Pharma America, INC. | $929.91 | 2023-2025 | Gemtesa, Aptiom |
| Lilly USA, LLC | $896.87 | 2019-2025 | Mounjaro, Jardiance, Zepbound |
| Neurocrine Biosciences, INC. | $849.98 | 2020-2025 | Ingrezza |
| Sunovion Pharmaceuticals INC. | $799.09 | 2019-2022 | |
| Novartis Pharmaceuticals Corporation | $661.98 | 2019-2025 | |
| Janssen Pharmaceuticals, INC | $658.12 | 2019-2023 | Xarelto |
| Glaxosmithkline, LLC. | $536.54 | 2019-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Merck Sharp & Dohme LLC | $534.53 | 2019-2025 | Verquvo, Belsomra, Steglatro |
Show all 61 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Aziz Kamali listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.